EUVIMEDEUVIMED entdecken
Crossref

Fetal-to-sickle hemoglobin index and clinical morbidity in hydroxyurea-treated sickle cell anemia

Nader Shakibazad, Fatemeh Anbaraki, Maryam Marzban

American Journal of Blood Research · 2026 · 16 (4) · 65-72

DOI: 10.62347/mayh4508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Blood Research, 2026. Verfasst von Nader Shakibazad und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Shakibazad, N., Anbaraki, F., & Marzban, M. (2026). Fetal-to-sickle hemoglobin index and clinical morbidity in hydroxyurea-treated sickle cell anemia. American Journal of Blood Research, 16(4), 65-72. https://doi.org/10.62347/mayh4508

Vancouver

Shakibazad N, Anbaraki F, Marzban M. Fetal-to-sickle hemoglobin index and clinical morbidity in hydroxyurea-treated sickle cell anemia. American Journal of Blood Research. 2026;16(4):65-72. doi:10.62347/mayh4508

BibTeX
@article{Shakibazad2026,
  author = {Shakibazad, Nader and Anbaraki, Fatemeh and Marzban, Maryam},
  title = {Fetal-to-sickle hemoglobin index and clinical morbidity in hydroxyurea-treated sickle cell anemia},
  journal = {American Journal of Blood Research},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {65--72},
  doi = {10.62347/mayh4508}
}
Kostenlos starten →